Furthermore, CCL20 is more highly expressed in KICH than in both KIRC and KIRP, supporting earlier research that mutations in the EGFR/Ras pathway promote tumor growth by increasing EGFR/Ras expression, which boosts the immune-activating chemokine CCL20 [88,89,90,91,92,93,94,95,96,97]. The gene discussed is CCL20; the disease is neoplasm.